Epigenetic Mechanisms in Sjögren’s Syndrome

Authors:

Christelle Le Dantec,¹ Amandine Charras,¹ Anne Bordron,¹ Wesley H. Brooks,^{2 *}Yves Renaudineau^1,3

1. INSERM ESPRI, ERI29/EA2216, LabEx IGO “Immunotherapy Graft Oncology”, Innovative Medicines Initiative PRECISESADS, Réseau épigénétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France
2. Department of Chemistry, University of South Florida, Tampa, Florida, USA
3. Laboratory of Immunology and Immunotherapy, Brest University Medical School, Hôpital Morvan, Brest, France
*Correspondence to [email protected]

Disclosure:

The authors have declared no conflicts of interest.

Acknowledgements:

This work was supported by the ‘Région Bretagne’, the ‘Association Française Gougerot-Sjögren et des Syndromes Secs’, and by the ‘Institut Français pour la Recherche Odontologique’. We are also grateful to Simone Forest and Geneviève Michel for their help in typing the paper. The research leading to these results received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115565, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution.

Received:

03.03.16

Accepted:

11.07.16

Citation:

EMJ. 2016;1[5]:21-28. DOI/10.33590/emj/10311584. https://doi.org/10.33590/emj/10311584.

Keywords:

Sjögren’s syndrome (SS), epigenetics, DNA methylation, histone acetylation, endogenous retrovirus

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.